PCN31 Economic Evaluation of Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) in the Brazilian Public Health Care System (SUS)  by Paladini, L. et al.
uninsuredwere associatedwith highermortality. CONCLUSIONS: The study found
that men who received the following treatments received radiation only, hormone
only, chose active surveillance, with co-morbidity and of advanced age had lower
survival benefit. Further, research that is foucsed on the specific cause of death
may help understand the impacts of treatment and covariates on prostate cancer
survival.
CANCER – Cost Studies
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OBJECTIVES:Vinorelbinewas not available in breast carcinoma treatment through
theCroatianNational Health Insurance (CNHI) PositiveDrugs List (PDL) and the aim
of our studywas to analyse the possible financial impact of vinorelbine inclusion to
the CNHI PDL. METHODS: A specific clinical guideline for vinorelbine reimburse-
ment through the CNHI PDL is proposed according to evidence-based medical cri-
teria and themain international guidelines. We have developed the budget impact
analysis (BIA) model and calculated the number of patients who will be treated
with vinorelbine in three-years’ period after the reimbursement following the pro-
posed clinical guideline. The share of vinorelbine has been estimated usingmarket
data and the price of vinorelbine has been calculated according to the Croatian
MoH Pricing Ordinance. The total costs for CNHI has been calculated using a refer-
ent scenario (without vinorelbine) and a scenario with vinorelbine reimbursement.
Monte Carlo simulation has been performed too. RESULTS: The total number of
patients who could be potential candidates for the vinorelbine treatment will be
200-300 per year. An average annual drug cost per patient is estimated at 628.50
USD. Monte Carlo simulation results in breast cancer treatment showed the cost of
1,010,000 USD per year in scenario without vinorelbine and declining costs in sce-
nario with vinorelbine from 879,299 USD in the first year of treatment to 614,411 in
the third year. The savings of vinorelbine introduction during the three-year period
will be 791,286 USD. CONCLUSIONS: The inclusion of vinorelbine to PDL, according
to the reimbursement criteria, demonstrates a net reduction of budget expendi-
tures for CNHI (savings) in the period of three years due to the effects of substitu-
tion of other cytostatic drugs with vinorelbine (only in the indication of breast
cancer). Our study supports the usage of vinorelbine from the clinical and phar-
macoeconomical aspect and it could give certain clinical benefits for these pa-
tients.
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OBJECTIVES: Treatment with 3 years (yrs) versus 1 yr of adjuvant imatinib (IM)
therapy for patients with surgically resected kit GIST with a high risk of recur-
rence has been shown to significantly improve recurrence-free survival (RFS) &
overall survival (OS).Therefore the budgetary impact of treating patients with GIST
with 3yrs vs. 1 yr of IM over a 3-year horizon was assessed. METHODS: A Markov
model was developed to predict GIST recurrence and treatment costs. Patients
enter the model after surgery and transition among three health states: free of
recurrence, recurrence, & death. Monthly recurrence & mortality rates were de-
rived from SSGXVIII/AIO clinical trial & published literature. Number of eligible
patients was estimated from Survival Epidemiology and End Results. Costs and
discontinuation rates were estimated from trial and published sources. The bud-
getary impact was estimated by comparing health care costs for 3 years versus 1yr
of IM and calculated as total & per member per month (PMPM) cost. Sensitivity
analyses were conducted. RESULTS: Themodel estimated the budgetary impact of
introducing 3 yr imatinib in a hypothetical health plan of 10 millionmembers with
36 surgically resected GIST incident patients. The model predicted that recurrence
or death would be avoided in 9 additional patients. The net budgetary impact per
patient per month would be $1090 in years 2 and $2574 in yearr 3, and cost $0.01
PMPM in years 2 & 3. Treatment with 3 years IM would increase the budget by 15%
in year 2 and 28% in year 3. Model results at yr 3 were sensitive to cost of imatinib
and recurrence rates. CONCLUSIONS: Treatment with 3 years of imatinib has been
shown to significantly improve RFS and OS. The budgetary impact associated with
this survival gain is predicted to be less than $0.01 PMPM.
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OBJECTIVES: To estimate the budget impact of everolimus as first-line metastatic
therapy for post-menopausal women who failed letrozole or anastrozole for treat-
ment of estrogen receptor positive (ER), human epidermal growth factor recep-
tor-2 negative (HER2-) metastatic breast cancer (MBC) from a third-party payer
perspective in the United States. METHODS: Pharmacy and medical budget im-
pacts were estimated over the first year of everolimus use in this specific indica-
tion. Published epidemiology data were used to estimate target population size.
Market share was assumed to be 100% exemestane before everolimus entry. Mar-
ket share for the combination therapy of everolimus and exemestane was pro-
jected to be 10%at the end of the first year after everolimus entry, andwas assumed
to increase linearly throughout the year. Components of pharmacy budget (whole-
sale acquisition cost of the therapies, daily dose, treatment duration, and copay-
ment) were obtained from unpublished data sources. Patients were assumed to be
on treatment until progression or death. Medical costs were estimated as the av-
erage costs for progression and non-progression weighted by the time in each
state. Progression and non-progression costs and time to progression for each
therapy were derived from published literature. All costs were reported in 2011 US
dollars. RESULTS: In a hypothetical health plan with 1 million members, the esti-
mated target population was 170. There were 17 patients expected to use the com-
bination therapy in the first year after everolimus entry, resulting in total incre-
mental plan costs of $0.025 per member per month (PMPM). While the pharmacy
budget was expected to increase by $0.038 PMPM, medical budget was expected to
decrease by $0.013 PMPM in the first year after everolimus entry. CONCLUSIONS:
Using everolimus for ER, HER2- MBC is expected to reduce medical budget due to
improved efficacy of combination therapy and increase pharmacy budget. The
total budget impact is relatively small.
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OBJECTIVES: In Mexico, melanoma represents approximately 8% of the total num-
ber of cases of skin cancer, becoming the third most common skin cancer, behind
basal cell carcinoma and squamous cell carcinoma. There are few published stud-
ies describing the cost of care for patients withmelanoma inMexico. The objective
of this study is to estimate the budgetary impact on the total cost of 1 year of
treatment of melanoma in Mexico, regarding the perspective of the Social Security
Mexican Institute (IMSS) the most important health institution, serving more than
55 million people in Mexico. METHODS: In order to obtain the prescriptive habits
for the treatment of melanoma and the direct costs (including chemotherapy, ra-
diation therapy, surgery, assessment of the patient, laboratory and diagnostic
studies), we conducted 10 semi-structured face to face interviews with oncology
specialists from IMSS. Epidemiological indicators like incidence, prevalence and
mortality were obtained from a systematic review of national and international
literature. We consider beneficiaries of the IMSS as the target population of this
study. The distribution for the small sample was obtained using a non-parametric
bootstrap approach. As result, we get patients with melanoma who sought care
and which were correctly diagnosed in stages 3 and 4 of the disease, that is, those
who are candidates to receive chemotherapy. Finally, results were analyzed and
validated by experts. RESULTS: The number of patients with a diagnosis of mela-
noma in IMSS over the 1-year time horizon was 274. The estimated direct cost in
2011 USD, associated to melanoma treatment for 1-year was USD$16,661. In base
case analysis, the 1-year net budget impact was USD$4.5million (IC-95%: $4.1 - $4.9
million dollars). CONCLUSIONS: The budgetary impact of the treatment of mela-
noma in IMSS represents 0.16% of total budget expenditure in 2010 ($ 2,900.56
million dollars).
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OBJECTIVES: Develop budget impact model to forecast total cost of treatment for
cutaneous T-cell lymphoma (CTCL) for US public and private payer.METHODS:The
clinical efficacy and safety data were obtained from the published pivotal study
results. Costs of adverse events were estimated based on claims database analysis,
AHRQ’s HCUP and CMS Medicare 2009 databases. Drug cost was estimated based
on 2011 AWP price. Epidemiology data were obtained from NCI-SEER and CDC
databases. A budget impact model was implemented over a period of five years,
based on a stable population and on different penetration and substitution rates of
newly approved therapy. Model was developed in excel based format. Blinded
Model design and outputs were tested with payers and KOLs. RESULTS: For rare
cancers such as CTCL, the budget impact of treatment with targeted cancer ther-
apies is in the range of $460,000-$530,000 per 1 million covered lives. The per
patient per member (PPPM) budget impact of this treatment is 46-53 cents. US
payers rated PPPM output as the one of the most important relevant outputs of
model. CONCLUSIONS: This budget impact model shows that new treatments for
rare forms of cancer are likely to have minimal budget impact on payers. PPPM
based outputs are more relevant to payers, than per patient treatment costs. How-
ever, an emerging concern is the total budget impact of all therapies indicated for
ultra-orphan disorders, which might be an important consideration for future
models.
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OBJECTIVES: MDS is an incurable and rare hematological disease that affects the
production of blood cells. Two hypomethylating agents for the treatment of MDS
are available in Brazil: azacitidine (AZA) and decitabine (DEC). Our aim was to
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compare the costs and outcomes of azacitidine (75 mg/m2 per day x 7 days every 4
weeks) vs. decitabine (45 mg/m2 per day x 3 days every 6 weeks) from the perspec-
tive of SUS. METHODS: We developed a Markov model to determine the cost-
effectiveness (CE) and 3-year budget impact of introducing AZA in the Brazilian
market. Patients considered were classified with IPSS Int 1, Int 2 and High risk. The
model considered progression to acute myelogenous leukemia (AML) and death as
the major outcomes of treatment. Outcomes, costs and epidemiological data were
obtained from a systematic review of literature and public sources. The costs of
adverse events and progressive disease were also included. A sensitivity analysis
was performed to test the robustness of the results. The currency conversion used
was BR$ 1.8: US$1.0. RESULTS: The cost effectiveness analysis showed better re-
sults for AZA compared to DEC resulting in lower costs and improved outcomes in
terms ofmortality rates and progression to AML. Over a 3-year time period, the use
of AZA was associated with a savings of BR$85,000 (US$45,000) compared to DEC.
Assuming that AZA would be given to 50% of patients with MDS in Brazil, it would
have a budgetary impact of BR$45,000 000 (US$25,000,000) for the public health care
system SUS. CONCLUSIONS:When compared to DEC, AZA showed improved out-
comes and lower costs as a treatment option for MDS in the Brazilian public health
system.
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OBJECTIVES: To estimate resource use, costs, and adverse events (AEs) among lung
cancer (LC) patients on standard chemotherapy with versus without an angiogen-
esis inhibitor (AGI) as adjunctive therapy. METHODS: Using Thompson Reuters
MarketScan®ResearchDatabase, patientswith a diagnosis code indicating primary
LC between 2005 and 2009 and at least one claim for an FDA approved AGI (bevaci-
zumab) within 8 days of chemotherapywere identified (AGI cohort). These patients
were matched 1:1 by demographics, cancer characteristics, and previous chemo-
therapy failure (30 days without chemotherapy) to patients on chemotherapy
with no claims for an AGI (No-AGI cohort). Patients were followed for 1 month.
All-cause per-patient-per-month (PPPM) resource use (inpatient, ER, and outpa-
tient), costs (in 2010 USD), and the prevalence of AEs were assessed. RESULTS: A
total of 766 patients were identified for each cohort (mean age 57.5 years, 47.9%
female). Mean follow-up was 10.4 and 11.6 months in the AGI and No-AGI cohorts.
All components of resource usewere similar between cohorts. All-cause total PPPM
cost was higher for the AGI cohort ($16,972 vs. $11,950 PPPM), primarily due to
higher outpatient infusion costs ($7,703 vs. $1,423). Over 52% of patients in each
cohort had 1 AE, and there were no statistically-significant differences in the
prevalence of AEs between groups. Themost common AEs were infusion reactions
(40.6% in AGI vs. 39.7% in No-AGI), dyspnea, (38.1% vs. 43.0%), nausea (37.6% vs.
33.8%), dehydration (32.9% vs. 34.1%), chest pain (28.9% vs. 31.5%), anemia (26.1%
vs. 24.4%), neutropenia (24.9% vs. 24.7%), thromboembolic events (17.2% vs. 20.6%),
and hemorrhage (15.4% vs. 12.7%). CONCLUSIONS: Prevalence of AEs was not sig-
nificantly different among LC patients on chemotherapy with and without an AGI.
Costs were higher in the AGI cohort, due to higher infusion costs. Future studies of
the cost-effectiveness of AGIs in LC patients based on real-world data are war-
ranted.
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OBJECTIVES:We performed an indirect comparison of efficacy and safety data for
two combination chemotherapy regimens (pemetrexed/cisplatin [PC] and bevaci-
zumab/cisplatin/gemcitabine [BCG]) approved for the first-line treatment of ad-
vanced, non-squamous non-small cell lung cancer (NSCLC). Our objectives were to
compare the survival outcomes and approximate mean incremental costs in
México for these two approved regimens using data from two phase III trials with a
common comparator (cisplatin/gemcitabine [CG]). METHODS: An indirect treat-
ment comparison was conducted using the Bucher method. One study compared
CG with BCG and included two doses of bevacizumab, but only the data for the 7.5
mg/kg dose of bevacizumabwas included in our analysis because this dose ismore
commonly used for NSCLC in México. The cost analysis included the estimated
costs of chemotherapy and costs related to the treatment of grade 3 or 4 adverse
events. Total chemotherapy drug costs were based on the mean number of cycles
of chemotherapy delivered in the two studies. Costs were calculated in 2011 Mex-
ican pesos and converted to US dollars. RESULTS: Significantly fewer patients ex-
perienced a grade3 adverse event with PC than BCG (risk difference: -10.50%; 95%
confidence interval [CI]: -18.4 to -2.71, p0.008). Overall survival was not signifi-
cantly different for PC vs BCG (hazard ratio [HR]0.87, 95% CI: 0.69 to 1.10, p0.242),
although in the individual trials PC had a significant survival advantage over CG
(HR0.84; 95% CI: 0.74 to 0.96, p0.011) while BCG (7.5 mg/kg bevacizumab) had no
survival advantage (HR0.93; 95% CI: 0.78 to 1.11. p0.420). The total estimated
costs were $20212 lower for PC than BCG. The cost savings for the PC regimenwere
predominantly due to lower pharmacy-related drug costs ($10501 vs $30121).
CONCLUSIONS: PChad lower estimated costs and less serious toxicity compared to
BCG and produced at least comparable survival outcomes.
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OBJECTIVES: The National Cancer Institute (NCI) estimates that cancer accounted
for approximately $124.57 billion dollars in direct costs in the United States in 2010.
NCI provides costs estimates on the initial, continuing and last ‘phase of care’ but
does not provide a breakdown by stage. This study aims to describe the costs
associated with stage 3 (S3) and stage 4 (S4) colon cancer (CC). METHODS: Data
from 1997-2005 of the Surveillance, Epidemiology, and End-Result-Medicare data-
set was used for this analysis. Individuals includedwere those diagnosed as having
AJCC S3 or S4 CC. Analyses excluded individuals whowere not eligible forMedicare
Parts A and B or those insured by Medicare HMO. Areas under the curve (AUC) for
direct medical costs were summed over a 40 week period, from time of CC diagno-
sis. Costs contributed were from beneficiaries who died from S3 and S4 CC and
were ever treated with chemotherapy. Costs were summed for S3 and S4 individ-
uals with at least 26 weeks of initial chemotherapy treatment. RESULTS: These
analyses identified 3549 individuals with S3 CC and 8194 individuals with S4 CC.
Over the 40 week observation period, the AUC for S3 and S4 CC was $52,145, and
$45,106, respectively. Meanweekly costs peaked at week 31 for S3 CC ($3425) and at
week 29 for S4 CC ($1,725). Among S3 and S4 individuals with at least 26 weeks of
initial chemotherapy treatment, the AUC was $35,890 for S3 CC and $49,871 for S4
CC. CONCLUSIONS: Among individuals who died with S3 or S4 CC and were ever
treated with chemotherapy, the costs associated with S3 cancer exceed those of S4
cancer over the 40 week observation period. Among those with at least 26 weeks of
initial chemotherapy and treatment, S3 chemotherapy treatment is less expensive
than S4 chemotherapy treatment.
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OBJECTIVES: This retrospective claims analysis aimed to compare erythropoiesis-
stimulating agent (ESA) dosing patterns and costs in chemotherapy-induced ane-
mia (CIA) hospital outpatients. METHODS: Electronic records from the Premier
hospital database (2006Q1-2011Q1) were used to identify outpatients aged 18
years that had a diagnosis for cancer, received chemotherapy during hospitaliza-
tion, and received epoetin alfa (EPO) or darbepoetin alfa (DARB).Exclusion criteria
were: a diagnosis of chronic kidney disease, diagnosis of myelodysplastic syn-
drome, receipt of renal dialysis, or receipt of both ESAs. The observation period
consisted of the outpatient continuous ESA episode, defined as the period fromfirst
to last outpatient visit with ESA use without a gap of more than one calendar
month between ESA visits. The ESA dose ratio (Units EPO: mcg DARB) was calcu-
lated using the mean cumulative dose of EPO and DARB. ESA treatment costs were
determined using cumulative dose and December 2010 wholesale acquisition
costs. RESULTS: A total of 7413 outpatient ESA episodes (EPO: 3979; DARB: 3434)
were identified. The EPO group had a lower proportion of females versus the DARB
group (61.7% vs. 67.7%, respectively; P0.001), however, EPO and DARB groups had
a similar mean age (62.0 vs. 61.8 years, respectively; P0.560) and duration of out-
patient episode (2.3months for both, P0.738). Themean cumulative dosewas EPO
212,752 Units and DARB 998mcg, resulting in a dose ratio (Units EPO: mcg DARB) of
213:1. Correspondingmean ESA treatment costs were higher for DARB than for EPO
(EPO: $3,223 vs. DARB: $5,352, P0.001). CONCLUSIONS: In this analysis of CIA
hospital outpatient records, a dose ratio (Units EPO: mcg DARB) of 213:1 was ob-
served. Mean ESA treatment costs were observed to be approximately 66% higher
for the DARB group than for the EPO group.
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OBJECTIVES: This retrospective analysis aimed to compare erythropoiesis-stimu-
lating agent (ESA) dosing patterns and costs in chemotherapy-induced anemia
(CIA) inpatients.METHODS: Electronic records from the Premier hospital database
(2006Q1-2011Q1) were used to identify inpatients aged 18 years that had a diag-
nosis for cancer, received chemotherapy during hospitalization, and received epo-
etin alfa (EPO) or darbepoetin alfa (DARB). Exclusion criteria were: a diagnosis of
chronic kidney disease, diagnosis of myelodysplastic syndrome, receipt of renal
dialysis, or receipt of both ESAs. The observation period consisted of the inpatient
stay. The ESA dose ratio (Units EPO: mcg DARB) was calculated using the mean
cumulative dose of EPO and DARB. ESA treatment costs were determined using
cumulative dose and December 2010wholesale acquisition costs. RESULTS:A total
of 20,132 inpatient stays (EPO: 15,221; DARB: 4,911) were identified. The EPO group
was older than the DARB group (65.0 vs. 63.7 years, respectively; P0.001), had a
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